



## (51) International Patent Classification:

*C07D 487/04* (2006.01) *A61K 31/4985* (2006.01)  
*A61J 3/06* (2006.01) *A61P 35/00* (2006.01)  
*A61J 3/10* (2006.01)

## (21) International Application Number:

PCT/IB2015/055561

## (22) International Filing Date:

22 July 2015 (22.07.2015)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/028,865 25 July 2014 (25.07.2014) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## (72) Inventors; and

(71) Applicants (for US only): **GONCALVES, Elisabete** [PT/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **TAUCHMANN, Christin** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **YEN, Shau-fong** [US/CH]; c/o Novartis Pharma AG, Postfach,

CH-4002 Basel (CH). **VIPPAGUNTA, Sudha** [US/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **ZONG, Zhixin** [CN/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US).

(74) Agent: **CHAPMAN, Jennifer**; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 (US).


## (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

## (54) Title: TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE

Figure 1.



(57) Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.



TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

— *with international search report (Art. 21(3))*

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*